AtriCure Inc. (ATRC)
34.73
0.34 (0.99%)
At close: Jan 14, 2025, 3:59 PM
34.69
-0.13%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 34 |
| Market Cap | 1.69B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.83 |
| PE Ratio (ttm) | -41.85 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 39 |
| Volume | 490,208 |
| Avg. Volume (20D) | 525,252 |
| Open | 34.65 |
| Previous Close | 34.39 |
| Day's Range | 33.87 - 36.15 |
| 52-Week Range | 18.94 - 39.05 |
| Beta | undefined |
About ATRC
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform tem...
Industry Medical - Instruments & Supplies
Sector Healthcare
IPO Date Aug 5, 2005
Employees 1,200
Stock Exchange NASDAQ
Ticker Symbol ATRC
Website https://www.atricure.com
Analyst Forecast
According to 8 analyst ratings, the average rating for ATRC stock is "Buy." The 12-month stock price forecast is $40, which is an increase of 15.16% from the latest price.
Buy 87.50%
Hold 0.00%
Sell 0.00%
Next Earnings Release
AtriCure Inc. is scheduled to release its earnings on Feb 13, 2025,
during market hours.
Analysts project revenue of $119.85M, reflecting a 12.49% YoY growth and earnings per share of -0.15, making a -28.57% decrease YoY.
Analysts project revenue of $119.85M, reflecting a 12.49% YoY growth and earnings per share of -0.15, making a -28.57% decrease YoY.
1 day ago ·
Source
+9.49%
Atricure shares are trading higher after announced...
Unlock content with
Pro Subscription
2 months ago ·
Source
+18.35%
Atricure shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on the stock and raised its price target from $34 to $40.
